

DIALYZER REUSE & HEPATITIS C IN HAEMODIALYSIS

**Thesis Submitted for the Partial Fulfillment of the
Master Degree in Internal Medicine**


By

Sherin Amin Sobhy

M.B., B.Ch.

54003

Supervised by



Prof. Dr. Sabry Gohar

Professor of Internal Medicine and Nephrology
Ain Shams University

Dr. Mohammad Mahmoud Abdel-Ghany

Assistant Professor of Internal Medicine and Nephrology
Ain Shams University
Co-Supervisor

Dr. Abdel Bassit Shaarawy Abdel Azeem


Lecturer of Internal Medicine and Nephrology
Ain Shams University


616.2623

S. A

**Faculty of Medicine
Ain Shams University**

1996







Acknowledgment

I would like to express my sincere and deep gratitude to Prof. Dr. Sabry Gohar, Professor of Internal Medicine and Nephrology, Ain Shams University, for his generous support and encouragement throughout this study. I have been honoured to work under his precious guidance. I also thank him for his valuable suggestions to overcome difficulties encountered in this work and to help improving the accuracy and clarity of the study. His assistance and kind advice are beyond acknowledgment.

I would like also to express my warm gratitude and appreciation to Dr. Mohammad Mahmoud Abdel-Ghany, Assistant Professor of Internal Medicine and Nephrology, Ain Shams University for his continuous guidance and effort throughout this work. I also thank him for his kind supervision, constant encouragement and advice.

I am deeply grateful to Dr. Abdel-Bassit Shaarawy, Lecturer of Internal Medicine and Nephrology, Ain Shams University, who offered me much of his time and effort to provide me with valuable advice and suggestions. I thank him for his great help and encouragement throughout this study.

I gratefully thank all the staff members of Dialysis units at Ain Shams University Hospital, Ain Shams Specialized Hospital, Nasr City Health Insurance Hospital and at the other 4 dialysis units at which the patients of this study are present for their great help.

I would like to thank Dr. Fayka Abdel-Hamied Abdellah, Clinical Pathology Specialist at Dialysis Laboratory in Ain Shams University Hospital.

Also, special thanks to Dr. Dalia Ezzat, Demonstrator at Community Medicine Department, Ain Shams University and Dr. Hassan El-Ghandour, Assistant Lecturer of Phoniatrics, Ain Shams University for their great effort and valuable time consumed to put this work at its final form.

Sherin Amin Sobhy

List of Contents

	Page
Introduction and Aim of the work	1
Review of Literature	
• Hepatitis C virus infection	3
• Introduction, Historical background of discovery of HCV and its identification	6
• Morphology and ultrastructure of HCV genome	8
• Epidemiology of HCV	15
• Diagnosis of HCV infection	28
• Prevention and control of HCV infection	47
• Management of HCV infection	51
• HCV and its relation with HBV in hemodialysis	54
• HCV and its relation with HIV in hemodialysis	55
• HCV infection in hemodialysis patients	56
• Dialyzer Reuse	64
• Quality control, personal and physical considerations and medicolegal aspects for informed consent.	84
Patients and Methods	89
Results	98
Discussion	126
Summary, Conclusion and Recommendations	138
References	142
Arabic Summary	

*Introduction
and
Aim of the Work*

INTRODUCTION

The improvement in research work for anti-viral antibodies reveals that hepatitis C virus spread is often greater than our present knowledge and that it is highly prevalent in chronic renal failure patients treated in dialysis units (*Giammaria et al., 1992*).

Hepatitis C virus infection is currently seen as an emerging problem in these units, not only for its rapidly increasing incidence, but also because of some doubts and uncertainty about the routes of its transmission among patients undergoing regular hemodialysis, in whom a condition of immunodeficiency is present (*Yamaguchi et al., 1990*).

In the present few years it has become clear that hemodialysis patients are at a high risk of acquiring HCV infection as several studies have reported a prevalence of positive anti HCV tests from 8% to over 50% in those patients and a considerable portion of those (i.e., 50% of cases) with acute hepatitis C, develop histologically proven chronic hepatitis (*Blumberg et al., 1995*).

There is still much we don't know about hepatitis C in dialysis units even though a majority of cases have been attributed to administration of blood transfusions contaminated with HCV, yet there is still a large number of cases acquiring HCV infection in dialysis units by means other than blood transfusion (*Caramelo et al., 1994*).

Also the meaning of the presence of the anti-HCV antibodies and the preventive measures to be taken are still controversial (*DiBenedetto et al., 1992*).

Introduction & Aim of the work

Dialyzer reuse is an increasingly common practice in the management of chronic renal failure patients maintained on regular hemodialysis (*Caramelo et al., 1994*). There is much contradiction between opinions about role of dialyzer reuse in the transmission of HCV infection. Some say that dialyzer reuse increases the possibility of transmitting HCV infection as they found in their study that patients in whom dialyzers were reused showed 60% positivity as compared to only 17% in those single use (*Kumar et al., 1994*). While many others support strongly the opinion that dialyzer reuse has nothing to do with HCV infection transmission as they found that seroconversion was not increased with dialyzer reuse (*Jadoul et al., 1993*).

Aim of the work:

The aim of this study is to help answering the on-going question: Is dialyzer-reuse considered a risk factor in transmitting HCV infection among hemodialysis patients or not?.

Review of Literature

Hepatitis C Virus Infection

Hepatitis: Which is defined as inflammation of the liver, can be caused by several different agents such as viruses, bacteria, drugs, toxins or excessive alcohol intake or autoimmune causes (*Abbott et al., 1990*).

Viral hepatitis: Is a condition caused by infection with one of several viruses which produce hepatic inflammation and necrosis leading to varying degrees of hepatic dysfunction. Clinically the liver may be enlarged and tender with or without jaundice and laboratory evidence of hepatocellular damage is invariably found in the form of elevated transaminases level (*Okner, 1992*). The severity ranges from subclinical infection or mild disease to occasional cases of fulminant disease which may be rapidly fatal. Infection may be self limited, completely resolving within 1 to 3 months without specific therapy or certain viruses may initiate a chronic process associated with cirrhosis and liver failure or cancer (*Weisiger, 1989*).

Hepatotropic viruses:

At least 5 different viruses are responsible for the major causes of viral hepatitis (HAV, HBV, HDV, HCV, HEV) and new HFV & HGV. All of which are endemic world wide (*Dienstag et al., 1991*).

Hepatitis A virus:

HAV is caused by a very small single stranded enterovirus type 72 and is 27 nm RNA virus within the pico RNA viridae family, transmitted by faeco-oral route and via intimate exposure (*Feinstone et al., 1973 and Dienstag et al., 1991*).

Hepatitis B virus:

HBV was the first recognized hepadna virus and classified as type I within hepadna viridae family. It was found to be double stranded circular DNA virus, 42 nm in diameter (*Francis, 1983*). HBV consists of outer viral envelop protein (containing the HB surface antigen) and viral nucleocapsid (the nucleus contains HB core antigen, the capsid contains HB envelop "the precore" antigen). The entire gene of HBV has been cloned (*Robinson et al., 1984*).

HBV is parentally and sexually transmitted and through close personal contact. Also perinatal transmission of HBV infection can occur in 60-80% of babies born to mothers infected with HBV who become carriers can spread the virus for the rest of their lives (*Abbott et al., 1990*) and (*Sherlock et al., 1993*)

Hepatitis D virus:

HDV is found only in patients who are infected with HBV and is caused by a defective small (36 nm), single stranded circular RNA virus. This defective delta agent requires the helper function of HBV for its survival, replication and expression. Infection with delta virus occurs either as a coinfection with HBV (both inoculated simultaneously at the same time) or as a superinfection of a HBV established case or HBV carrier and might lead to fulminant hepatitis or chronic progressive hepatitis (*Rizzetto et al., 1977 and Abbott, 1990*).

Non A Non B hepatitis:

NANBH includes at least 3 different agents or disease types uptill now. The first one is similar to HAV, causes epidemic form of disease or enterically transmitted acute NANBH and is a small single stranded (32-34 nm) RNA virus and is termed HEV with high mortality rate in pregnant women (*Alter, 1989 and Sherlock et al., 1993*). The second